Recent 8-K filings for UTHR

• May 6, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  UTHR Q1 revenue falls 2% to $781.5M; net income down 15%; $2B buyback

  Total revenues $781.5M (-2% YoY); net income $274.9M (-15%); diluted EPS $5.82 vs $6.63.

• March 30, 2026, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  United Therapeutics' TETON-1 Tyvaso meets primary endpoint; FVC improvement 130.1 mL (p<0.0001)

  TETON-1 met primary endpoint: change in absolute FVC by 130.1 mL vs placebo (p<0.0001) at week 52.

• March 9, 2026, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01 ◈ Material Agreements ×2

  United Therapeutics authorizes $2B buyback, enters $1.5B accelerated share repurchase with Citi

  Board approves up to $2B stock repurchase program through March 9, 2027.

• March 2, 2026, 6:59 PM ET other material materiality 0.85 positive item 7.01item 9.01

  United Therapeutics' ralinepag phase 3 meets primary endpoint; 55% risk reduction in PAH clinical worsening

  Ralinepag reduced risk of clinical worsening by 55% vs placebo (HR 0.45, p<0.0001) in phase 3 ADVANCE OUTCOMES study.

• February 25, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics reports record $3.18B FY2025 revenue; EPS $27.86 diluted

  FY 2025 revenue hit record $3.18B (+11% YoY); net income $1.33B ($27.86 diluted EPS) vs $1.20B ($24.64) in 2024.

• October 29, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  United Therapeutics reports record Q3 revenue $799.5M (+7% YoY); EPS $7.16 diluted, TETON-2 breakthrough

  Revenue $799.5M (+7% YoY); net income $338.7M (+10%); diluted EPS $7.16 vs $6.39.

• September 2, 2025, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  United Therapeutics' Tyvaso succeeds in TETON-2 IPF study, shows 95.6mL FVC improvement

  TETON-2 met primary endpoint: Tyvaso improved absolute FVC by 95.6 mL vs placebo at week 52 (p<0.0001).

• August 1, 2025, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01

  United Therapeutics enters $1B accelerated share repurchase agreements with Citibank

  Two ASR agreements with Citibank: $500M uncollared and $500M collared; total upfront payment $1B due Aug 4, 2025.

• July 30, 2025, 7:59 PM ET earnings materiality 0.90 positive item 2.02item 9.01

  United Therapeutics Reports Record Q2 2025 Revenue of $798.6M, Authorizes $1B Buyback

  Record total revenue of $798.6 million, up 12% year-over-year, driven by Tyvaso DPI growth of 22% to $315 million.

• April 30, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics reports record Q1 revenue of $794.4M, up 17% YoY, EPS $6.63

  Total revenues $794.4M (+17% YoY); net income $322.2M (+5%); diluted EPS $6.63 (+7% from $6.17).

• February 26, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  United Therapeutics reports record $2.88B revenue in FY2024, up 24% YoY

  Q4 revenue $735.9M (+20% YoY); net income $301.3M vs $217.1M in Q4 2023.

• October 30, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics Q3 revenue $748.9M (+23% YoY); net income $309.1M (+16%)

  Total revenues $748.9M, +23% YoY; net income $309.1M ($6.39 diluted EPS) vs $267.6M ($5.38).

• July 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics Q2 2024 revenue up 20% to $714.9M, EPS $5.85

  Total revenues $714.9M (+20% YoY); net income $278.1M ($5.85 diluted EPS) vs $259.2M ($5.24) in Q2 2023.

• May 1, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  United Therapeutics Q1 2024 revenue up 34% to $677.7M; net income $306.6M

  Total revenues $677.7M (+34% YoY); Tyvaso product line grew 56% to $372.5M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

13 positive 1 negative 5 neutral

source · UTHR on sec.gov